Amenorrhea and menopause are two different concepts. Amenorrhea Amenorrhea is characterized by the absence or cessation of menstruation. Primary amenorrhea means that a woman has never had a menstrual period. This kind of amenorrhea is less common and is mostly caused by genetic factors or congenital developmental defects, such as gonadal developmental abnormalities, gonadotropin secretion abnormalities, chromosomal abnormalities, and so on. Secondary amenorrhea, on the other hand, is the cessation of menstruation for 6 months or more than 3 menstrual cycles after normal menstruation has been established due to pathology or endocrine dysfunction of organs such as the hypothalamus, pituitary gland, ovaries and uterus. In these types of amenorrhea, a woman can undergo third generation IVF treatment when she has available small follicles in her ovaries, her uterine lining is ready for embryo transfer and there are indications for third generation IVF. Menopause Female menopause refers to menopause caused by physiological depletion of follicles in the female ovaries or ovarian failure due to ovarian surgery, radiotherapy and chemotherapy. At this time, there are no more eggs in the ovaries that can be utilized, and the fertility doctor is unable to produce eggs, therefore, IVF treatment cannot be performed. Third-generation IVF refers to pre-implantation genetic testing (PGT), including PGD (diagnosis) and PGS (screening). The main indications are advanced age, recurrent embryonic arrest or spontaneous miscarriage, and genetic risk of one of the spouses carrying abnormal chromosomes or abnormal genes. The cells tested in this technique are mostly derived from the outer trophoblast cells of blastocysts (cells that will develop into the placenta in the future; there is also a portion of cells known as the inner cell mass that will develop into the fetus in the future), which means that patients treated with PGT usually have to have all of their embryos cultured up to the blastocyst stage, and then select from them blastocysts that can be used for transplantation to undergo chromosomal or genetic testing, and then finally, select chromosomally/genetically normal blastocysts for The chromosomally/genetically normal blastocysts are then selected for transfer, while the chromosomally/genetically abnormal blastocysts are not utilized. The process of blastocyst rearing is a process of elimination of embryos, and there is actually a risk of failure of blastocyst rearing and total loss of embryos for women of high reproductive age (relatively small number of eggs and relatively poor quality of eggs). In addition, the diagnostic accuracy of the technique is not 100%. For example, when the chromosomes/genes of the outer trophoblast cells are different from those of the inner cell mass cells, the results may not be accurate. Finally, you need to consult with a genetics expert whether you should undergo third generation IVF treatment or not, and it is not something you can do just because you want to.